A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia

Blood

Volumn 117, Issue 6, 2011, Pages 1828-1833

  Fehniger, Todd A ^a   Uy, Geoffrey L ^a   Trinkaus, Kathryn ^b   Nelson, Alissa D ^a   Demland, Jeffery ^a   Abboud, Camille N ^a   Cashen, Amanda F ^a   Stockerl Goldstein, Keith E ^a   Westervelt, Peter ^a   DiPersio, John F ^a   Vij, Ravi ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LENALIDOMIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANEMIA; ARTICLE; BLAST CELL; BLOOD CELL COUNT; CANCER GROWTH; CANCER THERAPY; CELL COUNT; CENTRAL NERVOUS SYSTEM BLEEDING; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; DRUG MEGADOSE; DRUG WITHDRAWAL; FEMALE; FEVER; HUMAN; INFECTION; LEUKEMIA REMISSION; LOW DRUG DOSE; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RASH; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION;

EID: 79951495012     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-07-297143     Document Type: Article

References (34)

1. Ravandi F, Burnett AK, Agura ED, Kantarjian HM. Progress in the treatment of acute myeloid leukemia. Cancer. 2007;110(9):1900-1910. (Pubitemid 350041630)
2. Stone RM. Treatment of acute myeloid leukemia: state-of-the-art and future directions. Semin Hematol. 2002;39(3 suppl 2):4-10. (Pubitemid 34988409)
3. Tallman MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukemia. Blood. 2005;106(4): 1154-1163. (Pubitemid 41130866)
4. Ries LAG, Eisner MP, Kosary CL, et al. SEER Cancer Statistics Review, 1975-2004, National Cancer Institute. http://seer.cancer.gov/csr/1974-2004. Accessed June 1, 2008.
5. Estey E. Acute myeloid leukemia and myelodysplastic syndromes in older patients. J Clin Oncol. 2007;25(14):1908-1915. (Pubitemid 46854425)
6. Menzin J, Lang K, Earle CC, Kerney D, Mallick R. The outcomes and costs of acute myeloid leukemia among the elderly. Arch Intern Med. 2002; 162(14):1597-1603. (Pubitemid 34773427)
7. Stone RM. The difficult problem of acute myeloid leukemia in the older adult. CA Cancer J Clin. 2002;52(6):363-371. (Pubitemid 35446607)
8. Estey EH. General approach to, and perspectives on clinical research in, older patients with newly diagnosed acute myeloid leukemia. Semin Hematol. 2006;43(2):89-95.
9. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355(14): 1456-1465. (Pubitemid 44511560)
10. List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med. 2005;352(6):549-557. (Pubitemid 40204668)
11. Raza A, Reeves JA, Feldman EJ, et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood. 2008;111(1):86-93.
12. Bartlett JB, Michael A, Clarke IA, et al. Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. Br J Cancer. 2004;90(5):955-961. (Pubitemid 38495811)
13. Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood. 2002; 100(9):3063-3067. (Pubitemid 35217050)
14. Fehniger TA, Nelson A, Trinkaus K, et al. Phase II study of high dose lenalidomide as initial treatment for older acute myeloid leukemia patients: early results show a significant reduction of bone marrow blasts after 14 days of therapy. Blood. 2007;110:A916.
15. Fehniger TA, Nelson AD, Trinkaus K, et al. Preliminary results of a phase II study of high dose lenalidomide as initial therapy for acute myeloid leukemia in patients ≥ 60 years old. J Clin Oncol. 2008;26:A7058.
16. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood. 2000;96(13):4075-4083.
17. U.S. Food and Drug Administration. Lenalidomide package insert. http://www.accessdata.fda.gov/drugsatfda-docs/label/2006/021880s001.pdf. Accessed May 19, 2010.
18. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003; 21(24):4642-4649. (Pubitemid 46594039)
19. Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2009;115(3):453-474.
20. Stone RM, Berg DT, George SL, et al. Granulocytemacrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia: Cancer and Leukemia Group B. N Engl J Med. 1995;332(25): 1671-1677.
21. Grimwade D, Walker H, Harrison G, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood. 2001;98(5):1312-1320.
22. Anderson JE, Kopecky KJ, Willman CL, et al. Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study. Blood. 2002; 100(12):3869-3876. (Pubitemid 35396851)
23. Lowenberg B, Ossenkoppele GJ, van Putten W, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med. 2009;361(13):1235-1248.
24. Kantarjian HM, Erba HP, Claxton D, et al. Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J Clin Oncol. 2009;28(4):549-555.
25. Schiller GJ, O'Brien SM, Pigneux A, et al. Single-agent laromustine, a novel alkylating agent, has significant activity in older patients with previously untreated poor-risk acute myeloid leukemia. J Clin Oncol. 2009;28(5):815-821.
26. Tilly H, Castaigne S, Bordessoule D, et al. Lowdose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. J Clin Oncol. 1990;8(2):272-279. (Pubitemid 20056558)
27. Harousseau JL, Martinelli G, Jedrzejczak WW, et al. A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older. Blood. 2009;114(6):1166-1173.
28. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 2009;28(4):562-569.
29. Cashen AF, Schiller GJ, O'Donnell MR, DiPersio JF. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol. 2009;28(4):556-561.
30. Blum W, Garzon R, Klisovic RB, et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci U S A. 2010; 107(16):7473-7478.
31. Chandler JC, Klisovic RB, Phelps MA, et al. Phase I study of lenalidomide in acute leukemia: remissions in post-allogeneic relapse of acute myeloid leukemia. Blood. 2010;114:A841.
32. Fehniger TA, Byrd JC, Marcucci G, et al. Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13. Blood. 2009;113(5):1002-1005.
33. Sekeres MA, Maciejewski JP, Giagounidis AA, et al. Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes. J Clin Oncol. 2008;26(36):5943-5949.
34. Kotla V, Goel S, Nischal S, et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol. 2009;2(36):36.